Minerva Neurosciences (NERV) Cash & Equivalents (2013 - 2026)

Minerva Neurosciences' Cash & Equivalents history runs 14 years deep, the most recent figure standing at $32.7 million for Q1 2026.

• Quarterly Cash & Equivalents rose 88.89% year-over-year to $32.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.7 million (up 88.89% YoY) and the FY2025 annual result came in at $82.3 million, up 285.27% from the prior year.
• Cash & Equivalents was $32.7 million for Q1 2026 at Minerva Neurosciences, down from $82.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $82.3 million in Q4 2025 and bottomed at $12.3 million in Q3 2025.
• A 5-year average of $36.2 million and a median of $34.6 million in 2022 frame the typical range for Cash & Equivalents.
• Peak annual rise in Cash & Equivalents reached 285.27% in 2025, while the deepest fall reached 53.69% in 2025.
• Minerva Neurosciences' Cash & Equivalents stood at $34.6 million in 2022, then decreased by 20.85% to $27.4 million in 2023, then declined by 21.9% to $21.4 million in 2024, then jumped by 285.27% to $82.3 million in 2025, then tumbled by 60.32% to $32.7 million in 2026.
• Business Quant data shows NERV's Cash & Equivalents at $32.7 million in Q1 2026, $82.3 million in Q4 2025, and $12.3 million in Q3 2025.